BOTOX, NERVE STIMULATION DEVICES, MIRABEGRON, AND ANTICHOLINERGICS VERSUS BEST SUPPORTIVE CARE FOR OVERACTIVE BLADDER: AN UPDATED US COST-EFFECTIVENESS ANALYSIS

被引：0
|
作者：
Murray, Brian [1 ]
Miles-Thomas, Jennifer [2 ]
Sussman, David [3 ]
Park, Amy J. [4 ]
Chermansky, Christopher [5 ]
Nguyen, Victor [6 ]
Tung, Amy [7 ]
Gillard, Patrick [7 ]
Lalla, Anjana [7 ]
Nitti, Victor [8 ]
机构：
[1] Capital Reg Urol Surg, Albany, NY USA
[2] Eastern Virginia Med Sch, Virginia Beach, VA USA
[3] Rowan Univ, Sch Osteopath Med, Sewell, NJ USA
[4] Cleveland Clin, Cleveland, OH 44106 USA
[5] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[6] Curta Consulting Grp, Seattle, WA USA
[7] Allergan, Irvine, CA USA
[8] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
NEUROUROLOGY AND URODYNAMICS | 2021年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
M73
引用
收藏
页码：S157 / S157
页数：1
相关论文
共 50 条
  • [1] OnabotulinumtoxinA, Nerve Stimulation Devices, Mirabegron, and Anticholinergics Versus Best Supportive Care for Overactive Bladder: An Updated US Cost-Effectiveness Analysis
    Murray, Brian
    Miles-Thomas, Jennifer
    Sussman, David
    Park, Amy J.
    Chermansky, Christopher
    Nguyen, Victor
    Tung, Amy
    Gillard, Patrick
    Lalla, Anjana
    Nitti, Victor
    TOXICON, 2022, 214 : S42 - S43
  • [2] OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales
    Nick Freemantle
    Kristin Khalaf
    Clara Loveman
    Sanja Stanisic
    Dmitry Gultyaev
    Johanna Lister
    Marcus Drake
    The European Journal of Health Economics, 2016, 17 : 911 - 921
  • [3] OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales
    Freemantle, Nick
    Khalaf, Kristin
    Loveman, Clara
    Stanisic, Sanja
    Gultyaev, Dmitry
    Lister, Johanna
    Drake, Marcus
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2016, 17 (07): : 911 - 921
  • [4] COST-EFFECTIVENESS OF TREATING OVERACTIVE BLADDER WITH MIRABEGRON VERSUS ANTIMUSCARINICS IN MEXICO
    Ng, D. B.
    Parise, H.
    Dea, K.
    Espinosa, R.
    Anaya, P.
    Gooch, K.
    VALUE IN HEALTH, 2018, 21 : S266 - S267
  • [5] COST-EFFECTIVENESS OF MIRABEGRON VERSUS ANTIMUSCARINICS FOR THE TREATMENT OF OVERACTIVE BLADDER IN ARGENTINA
    Ramos, B.
    Sanchez Trujillo, L. A.
    Walker, D.
    Anaya, P.
    VALUE IN HEALTH, 2020, 23 : S378 - S378
  • [6] COST-EFFECTIVENESS OF BEST SUPPORTIVE CARE VS. ONABOTULINUMTOXINA, ORAL THERAPIES, PERCUTANEOUS TIBIAL NERVE STIMULATION, AND SACRAL NERVE STIMULATION FOR TREATING OVERACTIVE BLADDER-CLINICAL ASPECTS
    Dmochowski, Roger R.
    Hessami, Sam H.
    Guiltyaev, Dmitry
    Lister, Johanna
    Khalaf, Kristin M.
    Boer, Robert
    NEUROUROLOGY AND URODYNAMICS, 2017, 36 : S67 - S67
  • [7] Cost-Effectiveness of Percutaneous Tibial Nerve Stimulation Versus Extended Release Tolterodine for Overactive Bladder
    Chen, Heidi W.
    Bercik, Richard S.
    Werner, Erika F.
    Thung, Stephen F.
    JOURNAL OF UROLOGY, 2012, 187 (01): : 178 - 184
  • [8] COST-EFFECTIVENESS ANALYSIS OF MIRABEGRON VERSUS TOLTERODINE EXTENDED RELEASE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN THE UNITED STATES
    Xie, J.
    Zhou, Z. Y.
    Bui, C. N.
    Yan, Y.
    De, G.
    Runken, M. C.
    Wu, E. Q.
    VALUE IN HEALTH, 2012, 15 (07) : A457 - A457
  • [9] Economic evaluation of sorafenib versus best supportive care in advanced renal cell carcinoma: An updated cost-effectiveness analysis
    Gao, X.
    Shah, S.
    Reddy, P.
    Gondek, K.
    Pashos, C. L.
    VALUE IN HEALTH, 2008, 11 (03) : A61 - A61
  • [10] COST-EFFECTIVENESS OF PERCUTANEOUS TIBIAL NERVE STIMULATION VERSUS EXTENDED-RELEASE TOLTERODINE FOR OVERACTIVE BLADDER
    Chen, Heidi
    Bercik, Richard
    Thung, Stephen
    NEUROUROLOGY AND URODYNAMICS, 2011, 30 (02) : 247 - 247
12345